Literature DB >> 20564607

A rapid and most sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of alverine and its major metabolite, para hydroxy alverine, in human plasma: application to a pharmacokinetic and bioequivalence study.

Chinmoy Ghosh1, Vijay Jha, Ramesh Ahir, Sujal Shah, C P Shinde, Bhaswat S Chakraborty.   

Abstract

A rapid and highly sensitive method for the determination of alverine (ALV) and its metabolite, para hydroxy alverine (PHA), in human plasma using LC-MS/MS in positive ion electrospray ionization (ESI) in multiple reactions monitoring (MRM) mode was developed and validated. The procedure involves a simple solid phase extraction (SPE). Chromatographic separation was carried out on a Hypersil GOLD C(18) column (50 mm x 4.6 mm, 5 microm) with an isocratic mobile phase and a total run time of 1.5 min. The standard calibration curves showed excellent linearity within the range of 0.060-10.051 ng/mL for ALV and 0.059-10.017 ng/mL for PHA (r > or = 0.990). This method was successfully applied to a pharmacokinetic study after oral administration of alverine citrate 120 mg capsule in Indian healthy male volunteers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20564607     DOI: 10.1002/dta.130

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  3 in total

1.  Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy.

Authors:  Gaurang R Shah; Chinmoy Ghosh; Bharat T Thaker
Journal:  J Adv Pharm Technol Res       Date:  2010-07

2.  An improved LC-MS/MS method for the quantification of alverine and para hydroxy alverine in human plasma for a bioequivalence study.

Authors:  Dhiraj M Rathod; Keyur R Patel; Hiren N Mistri; Arvind G Jangid; Pranav S Shrivastav; Mallika Sanyal
Journal:  J Pharm Anal       Date:  2016-11-26

3.  Single Dose Study Assessing the Pharmacokinetic and Metabolic Profile of Alverine Citrate in Healthy Volunteers.

Authors:  Simona Rizea-Savu; Simona Nicoleta Duna; Roxana Colette Sandulovici
Journal:  Front Pharmacol       Date:  2021-01-20       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.